Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Inclusion Criteria: * Diagnosis of locally advanced or metastatic colorectal cancer. * No prior chemotherapy for metastatic disease. * Presence of radiologically and/or clinically documented disease. * Eastern Cooperative Oncology Group performance status of 0 or 1. * Adequate bone marrow, hepatic, renal function, Urine Creatinine Ratio (UPC) of \< * A female subject must not be pregnant or breast feeding. * Able to swallow and retain oral medications. Exclusion Criteria: * Has had any major surgery, chemotherapy, hormone therapy, investigational agent, or radiotherapy within the last 28 days * Prior treatment with pazopanib, or oxaliplatin. * Known contraindications to the use of oxaliplatin, capecitabine, 5-fluorouracil, or folinic acid. * Participation in any investigational study within 28 days prior to study treatment. * Women who are pregnant or lactating. * Poorly controlled hypertension. * A history of cardiovascular disease, arrhythmias, or significant ECG abnormalities. * Any history of stroke. * Current use of therapeutic warfarin. * Known brain metastases. * History of disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel. * Active infections or other serious illness. * History of allergy to platinum compounds or heparin. * Poor venous access.